三部门：对药品医疗器械质量安全内部举报人举报实施奖励

Core Viewpoint - The announcement by the National Medical Products Administration, Ministry of Finance, and State Administration for Market Regulation aims to enhance the internal supervision of drug and medical device quality safety by implementing a reward system for internal whistleblowers [2][12]. Group 1: Reward Conditions - Internal whistleblowers must meet specific conditions to qualify for rewards, including having a clear target and evidence of illegal activities, the matter not being previously known to authorities, and the case being resolved with administrative penalties or criminal prosecution [5][6]. - The definition of internal whistleblowers includes current employees, former employees within a year, and individuals with relevant business ties to the organization [3][4]. Group 2: Reporting Mechanism - The drug supervision authorities will maintain open channels for receiving reports, including a dedicated hotline and online platforms, and encourage organizations to display these reporting channels prominently [3][4]. - Upon receiving a report, authorities are required to process it according to established regulations and prioritize investigations into significant violations [4][6]. Group 3: Reward Implementation - Rewards will be determined collectively by the drug supervision department, and can include both monetary and non-monetary recognition [4][7]. - The funding for rewards will be included in the departmental budget and subject to oversight by financial and auditing departments [7][8]. Group 4: Protection of Whistleblowers - Measures will be taken to protect the personal information of whistleblowers, and any retaliation against them by employers will be subject to legal consequences [10][11]. - Organizations are encouraged to establish internal mechanisms for reporting safety risks and to actively promote a culture of safety and compliance [11][12].